271 related articles for article (PubMed ID: 27399694)
1. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
[TBL] [Abstract][Full Text] [Related]
2. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
3. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Xie H; Lin J; Thomas DG; Jiang W; Liu X
Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
[TBL] [Abstract][Full Text] [Related]
4. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma.
Wang L; Wu H; Wang L; Lu J; Duan H; Liu X; Liang Z
Diagn Pathol; 2016 Jul; 11(1):60. PubMed ID: 27391842
[TBL] [Abstract][Full Text] [Related]
5. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
6. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma.
Bachet JB; Maréchal R; Demetter P; Bonnetain F; Cros J; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
Eur J Cancer; 2013 Aug; 49(12):2643-53. PubMed ID: 23726265
[TBL] [Abstract][Full Text] [Related]
7. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
Fukumoto T; Watanabe T; Hirai I; Kimura W
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
[TBL] [Abstract][Full Text] [Related]
9. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
11. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
12. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
[TBL] [Abstract][Full Text] [Related]
13. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
14. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
15. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
[TBL] [Abstract][Full Text] [Related]
16. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.
Lewis R; Drebin JA; Callery MP; Fraker D; Kent TS; Gates J; Vollmer CM
HPB (Oxford); 2013 Jan; 15(1):49-60. PubMed ID: 23216779
[TBL] [Abstract][Full Text] [Related]
17. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
[TBL] [Abstract][Full Text] [Related]
18. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer.
Abe T; Ohuchida K; Endo S; Ookubo F; Mori Y; Nakata K; Miyasaka Y; Manabe T; Ohtsuka T; Nagai E; Oda Y; Nakamura M
Surgery; 2017 Apr; 161(4):951-958. PubMed ID: 27939334
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
